- Home
- TRX vs VERU Comparison
TRX vs VERU Comparison
Compare TRX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- VERU
- Stock Information
- Founded
- TRX 1990
- VERU 1971
- Country
- TRX Canada
- VERU United States
- Employees
- TRX N/A
- VERU N/A
- Industry
- TRX
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- VERU Health Care
- Exchange
- TRX Nasdaq
- VERU Nasdaq
- Market Cap
- TRX 95.9M
- VERU 85.5M
- IPO Year
- TRX N/A
- VERU 1990
- Fundamental
- Price
- TRX $0.35
- VERU $3.60
- Analyst Decision
- TRX Strong Buy
- VERU Strong Buy
- Analyst Count
- TRX 1
- VERU 3
- Target Price
- TRX $1.10
- VERU $33.33
- AVG Volume (30 Days)
- TRX 514.5K
- VERU 227.8K
- Earning Date
- TRX 07-15-2025
- VERU 08-12-2025
- Dividend Yield
- TRX N/A
- VERU N/A
- EPS Growth
- TRX N/A
- VERU N/A
- EPS
- TRX N/A
- VERU N/A
- Revenue
- TRX $47,731,000.00
- VERU $16,886,419.00
- Revenue This Year
- TRX $23.64
- VERU N/A
- Revenue Next Year
- TRX $51.77
- VERU N/A
- P/E Ratio
- TRX $327.04
- VERU N/A
- Revenue Growth
- TRX 29.98
- VERU 337.24
- 52 Week Low
- TRX $0.27
- VERU $2.64
- 52 Week High
- TRX $0.43
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- TRX 48.02
- VERU 36.46
- Support Level
- TRX $0.33
- VERU $2.64
- Resistance Level
- TRX $0.38
- VERU $3.98
- Average True Range (ATR)
- TRX 0.02
- VERU 0.40
- MACD
- TRX -0.00
- VERU 0.03
- Stochastic Oscillator
- TRX 35.40
- VERU 42.48
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.